Detail akcie Akebia Therapeutics online

Business Summary: Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Akebia Therapeutics Inc revenues decreased 18% to $113.7M. Net loss decreased 11% to $46.6M. Revenues reflect Development and commercialization segment decrease of 18% to $81.1M. Lower net loss reflects Development and commercialization segment loss decrease of 4% to $21.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.28 to -$0.22.